Intercept Pharmaceuticals, Inc. - ICPT STOCK NEWS

Intercept Pharmaceuticals (Nasdaq: ICPT) announced the presentation of two abstracts on obeticholic acid (OCA) at the NASH-TAG Conference 2023, taking place from January 5-7, 2023, in Park City, Utah. The data from the second interim analysis of the pivotal Phase 3 REGENERATE study highlight OCA's antifibrotic effects and favorable long-term safety profile. The conference will showcase results on a new analysis of the REGENERATE Trial and monitoring guidance reducing hepatic safety events. Note that OCA remains investigational and has not received FDA approval.

Intercept Pharmaceuticals (Nasdaq: ICPT) has resubmitted a New Drug Application (NDA) to the FDA for obeticholic acid (OCA), targeting treatment of pre-cirrhotic liver fibrosis due to nonalcoholic steatohepatitis (NASH). This NDA is underpinned by positive interim analyses from the Phase 3 REGENERATE study, demonstrating significant improvements in liver fibrosis without worsening NASH. The FDA is expected to classify this as a Class 2 resubmission, with a review timeline of six months. OCA is currently investigational and not yet approved for NASH treatment.

Intercept Pharmaceuticals (Nasdaq: ICPT) announced a study published in The American Journal of Pathology linking cholestatic liver disease to cognitive impairment.

The research discovered that obeticholic acid (OCA) may effectively alleviate cognitive issues associated with cholestatic conditions, demonstrating significant efficacy over other therapies like UDCA and bezafibrate.

These findings could enhance quality of life for patients suffering from primary biliary cholangitis (PBC), impacting the company’s therapeutic approach and market potential positively.

MORRISTOWN, N.J., Nov. 22, 2022, Intercept Pharmaceuticals (Nasdaq: ICPT) announced that Jerry Durso, President and CEO, and Andrew Saik, CFO, will participate in a fireside chat at Piper Sandler’s 34th Annual Healthcare Conference on December 1, 2022. The chat is scheduled from 2:00 p.m. to 2:25 p.m. ET, and interested investors can register through their representatives to attend. Intercept specializes in developing therapeutics for progressive non-viral liver diseases, including primary biliary cholangitis and nonalcoholic steatohepatitis.

Komodo Health announced a collaboration with Intercept Pharmaceuticals (NASDAQ: ICPT) to enhance clinical research using Komodo's platform. This partnership enabled a retrospective study on long-term outcomes for Ocaliva, a treatment for primary biliary cholangitis (PBC). The study demonstrated significant improvement in event-free survival for patients treated with Ocaliva. Despite previous challenges with a placebo-controlled study, this new approach leverages real-world evidence to validate treatment effectiveness, supported by the FDA's recent guidance on real-world data usage in regulatory submissions.

Intercept Pharmaceuticals (ICPT) announced its focus on developing INT-787 for severe alcohol-associated hepatitis (sAH), a condition with no approved therapies. Initial Phase 1 trial data showed a favorable safety profile in healthy adults. The company has initiated the Phase 2a FRESH study to evaluate INT-787 in sAH patients, targeting around 50 participants across the U.S., UK, and France. The drug demonstrated promising preclinical efficacy and a favorable pharmacokinetic profile, being significantly more water-soluble than existing treatments.

Intercept Pharmaceuticals has released pivotal data from its Phase 3 REGENERATE study, demonstrating that Obeticholic Acid (OCA) at 25 mg significantly improved liver fibrosis in patients with NASH. The study revealed a 22.4% response rate in patients taking OCA compared to 9.6% for placebo, with a notable doubling of efficacy in patients with advanced fibrosis. Safety assessments in 2,477 subjects showed manageable adverse events, primarily pruritus. The company aims to resubmit their New Drug Application for OCA by the end of 2022 following these encouraging findings.

Intercept Pharmaceuticals (NASDAQ: ICPT) announced that data from analyses on obeticholic acid (OCA) for treating primary biliary cholangitis (PBC) will be presented at The Liver Meeting® on November 6-7, 2022. The late-breaker poster highlights results from the COBALT trial, which showed no significant difference in clinical outcomes between OCA and placebo. However, external control data indicated a 61% reduction in risk of disease progression for OCA-treated patients. Additionally, the HEROES-US study demonstrated a 63% reduction in risk for death, liver transplant, or hospitalization in patients treated with OCA.

Intercept Pharmaceuticals reported U.S. net sales of $77.6 million for Ocaliva in Q3 2022, marking a 16.4% year-over-year growth. The company has increased its full-year Ocaliva non-GAAP adjusted net sales guidance to $340 million to $350 million. As of September 30, 2022, it holds $497.8 million in cash and equivalents. The company plans to resubmit its NDA for obeticholic acid in liver fibrosis due to NASH by year-end 2022, backed by positive Phase 3 study results. Long-term outcomes data support Ocaliva’s role in treating primary biliary cholangitis (PBC).